This study aims to evaluate the impact of long-term home non-invasive ventilation (NIV) on patients with COPD
Patients more than 18 year old.
Severe COPD (classified as GOLD stage Ⅲ and IV), confirmed by FEV₁/FVC < 70% and FEV₁ < 50% of the predicted value. (9)
Persistent hypercapnia (PaCO₂ ≥ 60 mmHg ≥2 weeks after resolution of acute exacerbation and compliant on optimal medical therapy with or without long term oxygen therapy
Other significant respiratory disorders (e.g,history suggestive OSA, Body Mass Index more than 30, pneumothorax, bullous lung disease, advanced interstitial lung diseases , restrictive thoracic wall diseases , neuromuscular disease).
Undergone intubation or tracheostomy prior to NIV initiation during the last 2 months.
Those using addictive narcotic medications.
Comorbidities and diseases that might confound survival outcomes (e.g., malignancy, advanced hepatic or renal diseases).